AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06075966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fusion group
Description: Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
Study NCT03672058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness tracker with goal setting and text message feedback
Description: Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
Study NCT03672058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitness Tracker only
Description: Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels
Study NCT04785755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution
Description: Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
Study NCT04785755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etilefrine
Description: Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
Study NCT03827720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSE Device
Description: Non-invasive radiofrequency (RF) sensor
Study NCT00745784 — intervention group
Intervention type: BEHAVIORAL
Intervention: in-person or telephone interview
Description: Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
Study NCT02140385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoplasty-Scarpa's fascia preservation
Description: Thicker abdominal flaps will be preserved during the surgery.
Study NCT02140385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoplasty-Scarpa's fascia ablation
Description: Thinner abdominal flaps will be preserved during surgery.
Study NCT02140385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy
Description: Post-operative lymphatic imaging will be conducted using a common radiographic medium
Study NCT02140385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Imaging
Description: Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
Study NCT02140385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal ultrasound
Description: Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
Study NCT02899507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic acid
Description: Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
Study NCT05594017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4mg)
Description: Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
Study NCT05594017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
Study NCT01404793 — intervention group
Intervention type: DRUG
Intervention: Rocuronium
Description: After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
Study NCT00198393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg/day, until progression
Study NCT00198393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m² D1 and D8 (D1=D28, until progression)
Study NCT00198393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m² D1 (D1=D22, until progression)
Study NCT01578642 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EndoStim LES Stimulation System
Description: The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer.
Study NCT03962283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 200mcg four times daily
Study NCT03962283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Rifaximin four times daily
Study NCT01559883 — intervention group
Intervention type: OTHER
Intervention: no intervention is being made
Description: This is a Non-Interventional Study (NIS)
Study NCT00053040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
Study NCT01250262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal medical care and follow up
Description: physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
Study NCT01250262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Lumbar Resistance Exercise Program
Description: lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
Study NCT01250262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Resistance Exercise Program
Description: exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
Study NCT00639054 — intervention group
Intervention type: PROCEDURE
Intervention: Bone marrow examination
Description: 7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
Study NCT01664806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien Triad monopolar generator
Description: Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
Study NCT01971112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins and minerals
Description: Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
Study NCT01971112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamins and minerals
Description: Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
Study NCT01778842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
Study NCT01778842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
Study NCT02161146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-229666
Description: One drop of AGN-229666 in the eye on Days 1 and 15.
Study NCT02161146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AGN-229666
Description: One drop of AGN-229666 in the eye on Days 1 and 15.
Study NCT02161146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle to AGN-229666
Description: One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Study NCT02161146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle to AGN-229666
Description: One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Study NCT01885208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Study NCT01885208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
Study NCT00920218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine 1437173A
Description: Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
Study NCT00920218 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine (saline)
Description: 1 or 3 doses of Placebo (saline) injected intramuscularly.
Study NCT00920218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo vaccine (saline)
Description: 1 or 3 doses of Placebo (saline) injected intramuscularly.
Study NCT01005316 — intervention group
Intervention type: DRUG
Intervention: Induction Therapy
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Study NCT01005316 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Study NCT03786471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health System-based Dementia Care
Description: Active comparator
Study NCT03786471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based Dementia Care
Description: Active comparator
Study NCT03786471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Control
Study NCT03922724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL-RIC
Description: e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
Study NCT03922724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRIC
Description: e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
Study NCT03922724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo HCT
Description: Stem cell transplant
Study NCT03922724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC
Description: e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
Study NCT03922724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25.
Study NCT03183596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20-60cc of 0.25% Bupivacaine
Study NCT03183596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2-4mg of Dexamethasone
Study NCT00961402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Control
Description: 6-month wellness control
Study NCT00961402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 6 month exercise intervention
Study NCT04102189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
Study NCT04102189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
Study NCT01005316 — intervention group
Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Study NCT01005316 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative plasma exchange/pheresis
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Study NCT01005316 — intervention group
Intervention type: PROCEDURE
Intervention: Short-term post-operative plasmapheresis
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Study NCT01005316 — intervention group
Intervention type: DRUG
Intervention: Immunoglobulins, Intravenous
Description: Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
Study NCT01005316 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
Study NCT00370760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral colchicine, dexamethasone, low molecular weight heparin, 5-FU
Study NCT00370760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00724685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naropeine (Ropivacaine)
Study NCT00724685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline
Study NCT01363921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO 1100
Description: Dialysis treatment with HCO1100
Study NCT04027803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-148
Description: single intravenous infusion of BCD-148 (900 mg)
Study NCT04027803 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Soliris
Description: single intravenous infusion of Soliris (900 mg)
Study NCT03575845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Informed Yoga
Description: Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
Study NCT00733161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive leg cycle exercise with stretching and resistance training
Description: Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
Study NCT00733161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and resistance training
Description: Stretching and resistance training everyday but no Passive leg cycle exercise
Study NCT00234871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril/verapamil
Description: 2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
Study NCT00234871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel (amlodipine/benazepril)
Description: 5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
Study NCT02559934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 Gel
Description: 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
Study NCT01007435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was supplied in vials.
Study NCT01007435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tocilizumab
Description: Placebo to tocilizumab was supplied in vials.
Study NCT01007435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
Study NCT01007435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
Study NCT01007435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to methotrexate
Description: Patients received placebo to methotrexate orally once a week.
Study NCT01734395 — intervention group
Intervention type: DRUG
Intervention: Galantamine
Description: This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
Study NCT01257230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat low dose
Description: IMP
Study NCT01257230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Respimat
Description: placebo representing comparator
Study NCT01257230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat high dose
Description: IMP
Study NCT00574730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP/Rituximab
Description: Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2
Study NCT00574730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG INTRON
Description: Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
Study NCT01895439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Study NCT01424891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80 mg
Description: treatment with 80 mg of simvastatin over a period of 8 weeks
Study NCT01424891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sim10/Eze10
Description: treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
Study NCT01424891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment with placebo over 8 weeks
Study NCT02209545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
Study NCT02209545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
Study NCT04233307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Telethermographic images
Description: Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
Study NCT00491855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose level 2.5 mg/kg given intravenously on day 1.
Study NCT00491855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
Study NCT00491855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
Study NCT00564863 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CS19 expressing ETEC strain
Description: Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
Study NCT05723965 — intervention group
Intervention type: OTHER
Intervention: As training material for deep learning model.
Description: Using labeled images as training materials for artificial intelligence to develop object detecting model.
Study NCT05723965 — intervention group
Intervention type: OTHER
Intervention: As materials for external validation for the buildup model.
Description: Using the external validation set to evaluate prediction rate and survival outcome.
Study NCT04082390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RELEASE
Description: Dietary supplement
Study NCT02161146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olopatadine
Description: One drop of olopatadine in the eye on Days 1 and 15.